溶瘤病毒
医学
黑色素瘤
病毒疗法
淋巴瘤
癌症研究
病毒
病毒学
肿瘤科
内科学
2019年冠状病毒病(COVID-19)
传染病(医学专业)
疾病
作者
Howard L. Kaufman,Dawid Maciorowski
标识
DOI:10.1038/s41571-021-00490-4
摘要
Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for the treatment of patients with recurrent melanoma. Now, a recent study in patients with primary cutaneous B cell lymphoma confirms prior results in melanoma and reveals new mechanisms of action. Herein, we discuss these findings and their implications for expanding the role of oncolytic viruses.
科研通智能强力驱动
Strongly Powered by AbleSci AI